Comparing therapeutic effects of Metformin and Pioglitazone in Polycystic ovary syndrome (PCOS)
Objective: To compare therapeutic effects of Metformin and Pioglitazone in Polycystic ovary syndrome (PCOS).
Methodology: In a randomized clinical trial, 100 women with PCOS were recruited during a one year period in Al-Zahra Hospital of Tabriz. These patients were randomized into two groups of 50 patients receiving either Metformin 500 mg(TDS), or Pioglitazone 15 mg(BID), for six months. Clinical and laboratory findings were compared between the two groups at the baseline and end of the study.
Results: Pregnancy frequency was higher in Metformin group. Amelioration of menstrual cycles, hirsutism, and laboratory tests, including FBS, Hyperinsulinemia, oral glucose tolerance test, 2hpps and insulin, free testosterone and prolactin was significant in both groups. The change of serum total cholesterol and HDL was not significant in the Pioglitazone group.
Conclusion: According to our results, Metformin is superior to Pioglitazone due to better influence on pregnancy and lipid profile.
- There are currently no refbacks.